

VANTAGE

Biomedical Partners





QUICK SCORE REPORT — SAMPLE

Company: NovaPulse Medical
Technology: Continuous cardiac monitoring patch
Report Date: April 2026

Overall Vantage Score

72 / 100 FAVORABLE

Domain Assessment

Domain A	78 / 100	
Domain B	65 / 100	
Domain C	74 / 100	
Domain D	71 / 100	

Domain identifiers are proprietary. Full labels and detailed breakdowns included in paid reports.

KEY RISK FLAG

1 terminal risk identified — regulatory pathway requires De Novo classification, not 510(k) as currently planned. Estimated 12-18 month timeline impact.

Benchmarked against 2,000+ life science outcomes | 98% classification accuracy

Executive Summary

NovaPulse Medical's continuous cardiac monitoring patch scores in the Favorable range, indicating strong commercial potential with addressable risks. The technology addresses a significant market need for remote patient monitoring in cardiology, with growing reimbursement pathways and clinical adoption.

The primary risk identified is a misclassified regulatory pathway. The device requires De Novo classification rather than the planned 510(k) submission. This represents a material timeline impact of 12-18 months and requires strategic repositioning of the regulatory strategy before FDA engagement.

Market positioning is strong with growing demand for remote cardiac monitoring. However, competitive differentiation needs strengthening. Several established players have achieved substantial market share; NovaPulse must articulate clear clinical and technical advantages to defend pricing and market position.

The IP portfolio shows adequate protection for core hardware and signal processing. However, the proprietary algorithm would benefit from additional patent claims around novel applications and methodologies to strengthen defensibility.

Recommended Next Steps

1. Upgrade to Full Founder Score for complete domain analysis and remediation roadmap
2. Schedule 30-minute findings call (included with Quick Score)
3. Request regulatory pathway deep-dive consulting engagement

CONFIDENTIAL — Prepared by Vantage Biomedical Partners | www.vantagebiomed.com

This is a redacted sample. Paid reports include proprietary scoring methodology, full domain analysis, and actionable remediation roadmaps.